Powered by: Motilal Oswal
2026-11-16 02:48:19 pm | Source: Emkay Global Financial Services Ltd
Buy Park Medi World Ltd for the Target Rs 350 by Emkay Global Financial Services Ltd
Buy Park Medi World Ltd for the Target Rs 350 by Emkay Global Financial Services Ltd

Park Medi World's (Park) 2QFY27 print was muted, with losses at recently commissioned new units (Panchkula, Rudrapur, and Agra) dragging overall portfolio margins (~380bps yoy in 1H). While the revenue trajectory remained strong (+25% yoy in 2Q) owing to bed adds, gross margins contracted ~550bps on the back of higher F&B costs (impact of ~200bps) and a change in case mix (skewed toward surgical procedures). The management upheld its FY27 guidance (revenue/EBITDA of Rs20.5/5.45bn) on the back of new units ramping up and the 2H bed expansion pipeline remaining on track (~17% of 1HFY27 capacity). We, however, expect a gradual improvement in margins given the steep capacity additions planned and cut our FY27/28E EBITDA by 9/8%. Improving payor mix and a higher share of surgical procedures should, however, aid cash conversion and profitability over the long term. We also note that Park remains largely shielded from trade margin caps on select onco drugs given its higher share of scheme patients. We maintain BUY and cut our Sep27E TP by ~7% to Rs350 from Rs375, based on 20x Sep-28E EV/EBITDA.

Mixed 2QFY27- Topline in line, margins disappoint

Park reported topline growth of 25% yoy (Rs5.1bn; in line with estimates) in 2Q, led by ARPOB growth of 13% yoy on the back of CGHS rate hikes (9%) and case mix (4%). IP/OP volumes grew 29% each yoy, while ALOS improved from 6.3 days in 2QFY26 to 5.4 days in 2QFY27. Occupancy remained flat sequentially at 55.8% in 2QFY27 owing to new bed additions (bed capacity increased 32% yoy). EBITDA declined 10% yoy to Rs1.0bn (-25% vs our estimates), while margin narrowed ~760bps yoy to 19.9%, driven by losses from newly commissioned units and higher consumable costs. PAT declined 29% yoy to Rs522mn, on account of the weak operating print and 40/71% increase in depreciation/tax expense. Payor mix for 2Q stood at 24%/76% for cash+TPA/government patients. CONGO mix improved to 52.4% from 45.4% (+700bps yoy). Working capital days as of Sep-26 came in at 123 days (FY26: 105 days); capex for 1H was Rs1.7bn.

A blip in the journey; reiterate BUY with Sep-27E TP of Rs350

The management has outlined a well-defined roadmap for bed expansions, as it plans to increase capacity by ~54% over the next 2 years. The management’s FY27 guidance (revenue/EBITDA growth of 24/19%) underpins its focus on profitable growth despite significant capacity additions in existing as well as new clusters. Park’s proven track record of acquiring assets and turning them around, while deepening its presence in existing clusters, lends comfort on the growth and margin trajectory, in our view. With an improving payor mix (target of 70/30 scheme and cash), focus on high-acuity procedures and an affordable healthcare service proposition, we believe Park’s return profile will remain healthy despite aggressive expansion plans. We expect Park to clock 25% revenue CAGR over FY26-29E, on the back of ARPOB/OBD CAGR of 5/19%. We thus view the 2Q operating performance as an aberration in the overall profitable growth journey. Key risks: delays in collections from government-scheme patients and execution risks in new markets.

 

For More  Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH0000003

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here